CCLA Investment Management Purchases 212,337 Shares of Danaher Corporation $DHR

CCLA Investment Management increased its holdings in Danaher Corporation (NYSE:DHR) by 41.3% during the 3rd quarter, HoldingsChannel reports. The firm owned 725,976 shares of the conglomerate’s stock after buying an additional 212,337 shares during the period. Danaher accounts for approximately 2.3% of CCLA Investment Management’s portfolio, making the stock its 15th largest position. CCLA Investment Management’s holdings in Danaher were worth $143,808,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of DHR. White Pine Capital LLC grew its stake in shares of Danaher by 1.4% in the 2nd quarter. White Pine Capital LLC now owns 3,494 shares of the conglomerate’s stock worth $690,000 after buying an additional 49 shares in the last quarter. Boyd Watterson Asset Management LLC OH lifted its holdings in shares of Danaher by 2.1% in the 2nd quarter. Boyd Watterson Asset Management LLC OH now owns 2,524 shares of the conglomerate’s stock valued at $499,000 after acquiring an additional 51 shares during the last quarter. Worth Financial Advisory Group LLC grew its position in Danaher by 4.6% in the second quarter. Worth Financial Advisory Group LLC now owns 1,195 shares of the conglomerate’s stock worth $236,000 after acquiring an additional 53 shares in the last quarter. Bruce G. Allen Investments LLC increased its stake in Danaher by 13.1% during the second quarter. Bruce G. Allen Investments LLC now owns 467 shares of the conglomerate’s stock worth $92,000 after acquiring an additional 54 shares during the last quarter. Finally, Texas Bank & Trust Co raised its position in Danaher by 1.6% during the second quarter. Texas Bank & Trust Co now owns 3,567 shares of the conglomerate’s stock valued at $705,000 after purchasing an additional 55 shares during the period. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Trading Up 0.2%

NYSE DHR opened at $224.78 on Monday. The stock has a market cap of $158.77 billion, a PE ratio of 46.35, a PEG ratio of 4.36 and a beta of 0.89. Danaher Corporation has a 12 month low of $171.00 and a 12 month high of $258.23. The company’s 50-day moving average price is $220.37 and its 200-day moving average price is $207.11. The company has a current ratio of 1.52, a quick ratio of 1.10 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Monday, October 20th. The conglomerate reported $1.89 earnings per share for the quarter, beating analysts’ consensus estimates of $1.72 by $0.17. The company had revenue of $6.05 billion during the quarter, compared to analyst estimates of $6 billion. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The firm’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same quarter last year, the business posted $1.71 EPS. Equities research analysts forecast that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Friday, December 26th will be paid a $0.32 dividend. The ex-dividend date of this dividend is Friday, December 26th. This represents a $1.28 annualized dividend and a yield of 0.6%. Danaher’s dividend payout ratio is 26.39%.

Insiders Place Their Bets

In other Danaher news, Director Teri List sold 3,298 shares of Danaher stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $226.50, for a total transaction of $746,997.00. Following the completion of the sale, the director directly owned 20,762 shares of the company’s stock, valued at $4,702,593. The trade was a 13.71% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Brian W. Ellis sold 21,776 shares of the company’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total value of $4,773,952.48. Following the completion of the sale, the senior vice president owned 14,553 shares of the company’s stock, valued at $3,190,454.19. This represents a 59.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 30,248 shares of company stock worth $6,609,663 in the last ninety days. 11.20% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on DHR shares. Deutsche Bank Aktiengesellschaft lifted their target price on Danaher from $235.00 to $250.00 and gave the stock a “buy” rating in a report on Wednesday, October 22nd. Redburn Partners set a $220.00 price objective on shares of Danaher in a research note on Wednesday, October 8th. Barclays increased their target price on shares of Danaher from $225.00 to $250.00 and gave the company an “overweight” rating in a research note on Wednesday, October 22nd. The Goldman Sachs Group started coverage on shares of Danaher in a report on Tuesday, December 9th. They issued a “buy” rating and a $265.00 target price for the company. Finally, Bank of America cut their price target on shares of Danaher from $230.00 to $220.00 and set a “buy” rating on the stock in a report on Monday, September 22nd. Twenty-one investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $248.25.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.